Help us: Donate
Follow us on:
×

Tag: David Sinclair

Sinclair Why We Age
David Sinclair, PhD, esteemed molecular geneticist at Harvard, believes that aging is a disease that should be attacked at its roots. Furthermore, he believes if we are to make efficient and sensible use our medical resources, we must move away from the "whack-a-mole" approach to treating individual age-related diseases. In his first book, Lifespan: Why...
LSN Resveratrol
On this episode of Lifespan News, Ryan O'Shea focuses on a recent controversy involving David Sinclair and the well-known supplement resveratrol. Script There’s been some controversy recently regarding resveratrol and the work of Dr. David Sinclair. In 2003, he published research on yeast in the journal Nature that said - “We show that the potent...
Debate
A significant debate has originated regarding the inclusion of MG2A, a code for old age, in the ICD-11 for Mortality and Morbidity Statistics. What is the ICD-11? The 11th revision of the International Classification of Diseases, which goes into effect this month, is managed by the World Health Organization. Its stated purpose is twofold: allows...
Three buildings
Another special purpose acquisition company (SPAC) focused on longevity and rejuvenation biotechnology has appeared recently, and with the addition of research rockstars David Sinclair and Peter Attia, it could mean a bright future for healthy longevity. We recently talked about how SPACs could transform the longevity research industry in Humacyte in Deal to Develop Prosthetic...
Mouse eye
Researchers at the Sinclair Lab at Harvard Medical School have restored lost vision to old mice, and mice with damaged retinal nerves, using partial cellular reprogramming. The aged cells can be reset to become younger again using this approach and are better at repairing damaged tissue. The approach has huge potential in the treatment of...
Investment
More and more investors are starting to get interested in technologies that are being developed to slow or even reverse aging as therapies are starting to reach human trials. Recently, I attended the Longevity Investors Conference to learn more about investments being made towards anti-aging research. A shift towards doing something about aging The current...